Advanced cancer pain management sales will expand through 2036, with monoclonal antibodies holding 46.8% of the drug class in 2026. The market was valued at USD 7.80 billion in 2025 and is expected to be worth USD 12.45 billion by 2036, creating an incremental opportunity of USD 4.31 billion.